Argus analyst Jasper Hellweg raised his price target on Iqvia to $136 and kept his Buy rating, citing its position as the industry leader in contract research organization to benefit from "steady biopharmaceutical funding and a healthy backlog". Hellweg notes that while the company has faced headwinds in implementing its Orchestrated Customer Engagement platform, it also saw margin growth in Q2. The analyst also points to Iqvia's discount valuation, with the stock trading at 22.6-times his expected FY18 earnings, which is below the peer group average of 23.5-times, and believes a higher valuation is warranted given its "new product offerings, technological innovation, and above-peer-average revenue and earnings growth prospects".